{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:15:22Z","timestamp":1793531722416,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jconrel.2021.08.051","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:08:33Z","timestamp":1630580913000},"page":"804-812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies"],"prefix":"10.1016","volume":"338","author":[{"given":"Anne M.","family":"Talkington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan D.","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Nyborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.08.051_bb0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/2042098617727714","article-title":"Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations","volume":"8","author":"Guttmann","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167935","article-title":"A therapeutic uricase with reduced immunogenicity risk and improved development properties","volume":"11","author":"Nyborg","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0015","unstructured":"Highlights of Prescribing Information: Krystexxa\u00ae (pegloticase) in: Injection label, pp. 1\u201314."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0020","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthrit. Res. Ther."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0025","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthrit. Res. Ther."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/TCRM.S6043","article-title":"New advances in the treatment of gout: review of pegloticase","volume":"6","author":"Reinders","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2146\/ajhp130571","article-title":"Investigation of pegloticase-associated adverse events from a nationwide reporting system database","volume":"71","author":"Gentry","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0045","series-title":"Polymer-Protein Conjugates","first-page":"103","article-title":"5-Immunological responses to PEGylated proteins: anti-PEG antibodies","author":"Elsadek","year":"2020"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0050","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1073\/pnas.1512465112","article-title":"Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0055","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0060","series-title":"Engineering of Biomaterials for Drug Delivery Systems","first-page":"363","article-title":"14 - PEGylation and its alternatives: a summary","author":"Abbina","year":"2018"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cbpa.2015.08.009","article-title":"Protein-polymer conjugation\u2014moving beyond PEGylation","volume":"28","author":"Qi","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0070","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1039\/c0py00406e","article-title":"Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure\u2013property relationships to better defined therapeutics","volume":"2","author":"Barz","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0075","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1002\/anie.201808615","article-title":"Revealing the immunogenic risk of polymers","volume":"57","author":"Li","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0080","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cmdc.201600374","article-title":"Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation","volume":"11","author":"van Witteloostuijn","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0085","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/anie.201814275","article-title":"Proactively reducing anti-drug antibodies via immunomodulatory bioconjugation","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0041-008X(71)90312-7","article-title":"Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization","volume":"18","author":"Carpenter","year":"1971","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jps.3030360508","article-title":"The toxicity of high molecular weight polyethylene glycols; chronic oral and parenteral administration","volume":"36","author":"Smyth","year":"1947","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/hae.12762","article-title":"Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates","volume":"22","author":"Stidl","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0110","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"127","article-title":"PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals","author":"Webster","year":"2009"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0115","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.procbio.2016.09.029","article-title":"Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins","volume":"52","author":"Wan","year":"2017","journal-title":"Process Biochem."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311-312","author":"McSweeney","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0140","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jconrel.2020.10.011","article-title":"Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice","volume":"329","author":"McSweeney","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.kint.2017.04.031","article-title":"Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders","volume":"93","author":"Lu","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0155","article-title":"Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0165","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2018.06.002","article-title":"A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse","volume":"284","author":"McSweeney","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0175","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nprot.2010.13","article-title":"Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine","volume":"5","author":"Vosjan","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0185","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.4049\/jimmunol.1202017","article-title":"Fc\u03b3RIIb on liver sinusoidal endothelium clears small immune complexes","volume":"189","author":"Ganesan","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0190","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1016\/j.biomaterials.2011.03.035","article-title":"In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers","volume":"32","author":"Merkel","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0195","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","article-title":"Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice","volume":"83","author":"Yamaoka","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0200","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.drudis.2014.06.002","article-title":"Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?","volume":"19","author":"Baumann","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejps.2015.10.020","article-title":"Pharmacokinetics, tissue distribution and excretion of 40kDa PEG and PEGylated rFVIII (N8-GP) in rats","volume":"87","author":"Bj\u00f8rnsdottir","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0215","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0220","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.18.02439","article-title":"Antibodies predict pegaspargase allergic reactions and failure of rechallenge","volume":"37","author":"Liu","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0225","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0230","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0235","unstructured":"Product Information Annex: KRYSTEXXA 8 mg concentrate for solution for infusion, in: Product Information, European Medicines Agency, European Public Assessment Report, pp. 1\u201327."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheumat. Dis. Clin. N. Am."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0245","doi-asserted-by":"crossref","first-page":"E10069","DOI":"10.1073\/pnas.1811892115","article-title":"mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3","volume":"115","author":"Shi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0250","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/lt.20072","article-title":"Effect of sirolimus on infection incidence in liver transplant recipients","volume":"10","author":"Fisher","year":"2004","journal-title":"Liver Transplant."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0255","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/acr2.11187","article-title":"Adverse effects of low-dose methotrexate in a randomized double-blind placebo-controlled trial: adjudicated hematologic and skin cancer outcomes in the cardiovascular inflammation reduction trial","volume":"2","author":"Vanni","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0260","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0049-0172(95)80009-3","article-title":"Infections during low-dose methotrexate treatment in rheumatoid arthritis","volume":"24","author":"Boerbooms","year":"1995","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0265","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1039\/c0py00406e","article-title":"Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics","volume":"2","author":"Barz","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0270","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated biopharmaceuticals: current experience and considerations for nonclinical development","volume":"43","author":"Ivens","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0275","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/toxsci\/42.2.152","article-title":"Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins","volume":"42","author":"Bendele","year":"1998","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.06.007","article-title":"Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs","volume":"306","author":"Bavli","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1248\/yakushi.128.233","article-title":"Accelerated blood clearance (ABC) phenomenon induced by administration of PEGylated liposome","volume":"128","author":"Ishida","year":"2008","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0290","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0295","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.08.051_bb0300","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.jconrel.2021.08.051_bb0305","series-title":"Proceedings of the Society for Experimental Biology and Medicine","first-page":"16","article-title":"Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins","volume":"75","author":"Kaliss","year":"1950"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100465X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100465X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:18:19Z","timestamp":1759162699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592100465X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":61,"alternative-id":["S016836592100465X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.051","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}